Q-omics provides the consensus-scored CDC26P1 profile across patient tissues and cancer cell-line models. CDC26P1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, CDC26P1 is differentially expressed in 3, with the highest sampling consensus in KICH. Additionally, CDC26P1 RNA expression shows 7,362 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight LGG, KICH, and READ as cancer lineages where CDC26P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC26P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC26P1 survival associations across molecular data types. CDC26P1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC26P1 RNA expression–survival associations across cancer types. High CDC26P1 expression shows unfavorable associations in LGG and BLCA, but favorable associations in COAD, SKCM, READ and PAAD. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for CDC26P1 RNA expression.
This table summarizes CDC26P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CDC26P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC26P1 shows lower tumor expression in KICH and higher tumor expression in BRCA and ESCA. The KICH box plot shows higher CDC26P1 RNA expression in normal versus tumor tissue (log2 FC = −0.785, t-test p = .035).
This table shows molecular features associated with CDC26P1 in patient tissues and cancer cell lines. In patient samples, CDC26P1 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set.
